Axis-Shield PoC AS
Search within our site
search
About us Contacts Axis-Shield plc Axis-Shield USA
Home


Login for distributors login
Products  \  Afinion  \  Tests  \  Afinion HbA1c news

Axis-Shield Afinion HbA1c Patent Granted In USA

Dundee, Scotland, 27 June, 2008: Axis-Shield (LSE:ASD, OSE:ASD), the international in-vitro diagnostics company, today announces that it has received notice of approval of its US patent application governing the measuring methodology for HbA1c within the Afinion cassette for detection of this important marker of diabetic patient compliance.

Afinion HbA1c Patent

The patent protects technology which improves HbA1c stability, precision and
accuracy and has resulted in a longer product shelf-life with improved performance. The invention may also have utility for the well-established NycoCard™ product for the same marker.

180 million people worldwide have diabetes

The World Health Organisation estimates that more than 180 million people worldwide have diabetes and that this number is likely to more than double by 2030. It is generally agreed that HbA1c blood levels should be tested four times a year in people with Type I diabetes and twice yearly in those with Type II diabetes. The Afinion Point-of-Care Analyser and the HbA1c test is now becoming established in the US physician’s office test market as the ease-of-use and reliability of the system are demonstrated.

Comments from Axis-Shield CEO

Ian Gilham, Axis-Shield CEO, commented: “We are developing a strong franchise for measuring HbA1c in diabetes through Afinion™ and NycoCard™ at the point-of-care and on the Abbott AxSYM® analyser in the hospital laboratory. We are pleased to have been granted this patent as part of our programme to protect our innovative technology in the expanding near-patient testing marketplace.”

Enquiries:
Axis-Shield plc Tel: +44 (0)1382 422000
Ian Gilham, Chief Executive Officer
Ronny Hermansen, Finance Director
Financial Dynamics Tel: +44 (0)207 831 3113
David Yates / Emma Thompson

Notes to Editors:
Axis-Shield is an international in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specialises in the supply of instruments and tests for the rapidly growing physician’s office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, and diabetes.

For more information on Axis-Shield, please refer to www.axis-shield.com

No documents found